ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

IRLA vs FENC // OPERATING MARGIN

IRulya Therapeutics Inc. (NASDAQ) VS. Fennec Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: IRLA 1 — FENC 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IRLA VS. FENC) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC IRLA FENC SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -25.90% -9.10 FENC /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -12.19% -3.25% -8.94 FENC /fcf-yield <GO>
Operating Margin ACTIVE — -14.10% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — -6.10% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 3.31 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 2/9 -1.00 FENC /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 52.5 46.3 +6.20 IRLA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $357.2M $358.7M -$1.5M FENC /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR IRLA REV FENC REV IRLA GROSS % FENC GROSS % IRLA FCF FENC FCF
FY 2025 $162.6M $44.6M — — -$41.8M -$12.5M
FY 2024 $160.4M $47.5M — — -$32.2M $27.0M
FY 2023 $96.9M $21.3M — — -$18.3M -$17.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IRLA // BETA —
FENC // BETA —